Curated News
By: NewsRamp Editorial Staff
May 28, 2024
Clene Showcases CNM-Au8(R) at Investor Conferences
Discuss on Reddit
Discuss on SubstackTLDR
- Clene's participation in investor conferences provides insight into their lead drug candidate CNM-Au8(R), offering a potential advantage for investors.
- CNM-Au8(R) is an oral suspension designed to restore neuronal health and function by increasing energy production and utilization, with over 600 years of exposure in clinical trials.
- Clene's therapy has the potential to improve neuronal health and treat neurodegenerative diseases, offering hope for patients and a better tomorrow.
- The Mizuho Neuroscience Summit 2024 and other conferences provided Clene with the opportunity to present CNM-Au8(R), a promising breakthrough in neurodegenerative disease treatment.
Impact - Why it Matters
This news matters as it highlights the participation of Clene in important investor conferences, providing insight into the development of CNM-Au8(R) and its potential impact on treating neurodegenerative diseases.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, recently participated in three investor conferences, presenting its lead drug candidate CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization. CNM-Au8(R) has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Showcases CNM-Au8(R) at Investor Conferences
